Published TCIMAIL newest issue No.201
Maximum quantity allowed is 999
CAS RN: 135062-02-1 | Product Number: R0179
Repaglinide
Purity: >98.0%(T)(HPLC)
- (S)-(+)-2-Ethoxy-4-[N-[1-(2-piperidinophenyl)-3-methyl-1-butyl]aminocarbonylmethyl]benzoic Acid
* Stock available in Belgium: Shipment on the same day
* Stock available in Japan: Please check the Shipping Simulation for estimated shipments. (excludes regulated items and dry ice shipments)
| Product Number | R0179 |
Purity / Analysis Method
|
>98.0%(T)(HPLC) |
| Molecular Formula / Molecular Weight | C__2__7H__3__6N__2O__4 = 452.60 |
| Physical State (20 deg.C) | Solid |
Storage Temperature
|
Refrigerated (0-10°C) |
| Condition to Avoid | Heat Sensitive |
| CAS RN | 135062-02-1 |
| Reaxys Registry Number | 8238956 |
| PubChem Substance ID | 253661221 |
| Merck Index (14) | 8136 |
| MDL Number | MFCD00906179 |
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 131.0 to 135.0 °C |
| Specific rotation [a]20/D | +7.0 to +10.0 deg(C=1,MeOH) |
| Melting Point | 133 °C |
| Specific Rotation | 9° (C=1,MeOH) |
| Pictogram |
|
| Signal Word | Warning |
| Hazard Statements | H302 : Harmful if swallowed. H361 : Suspected of damaging fertility or the unborn child. H362 : May cause harm to breast-fed children. |
| Precautionary Statements | P263 : Avoid contact during pregnancy and while nursing. P260 : Do not breathe dust. P202 : Do not handle until all safety precautions have been read and understood. P201 : Obtain special instructions before use. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection/ hearing protection. |
| RTECS# | DI0876305 |
| HS Number | 2933399999 |
References
- Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes
- Repaglinide, a novel, short-acting hypoglycemic agent for type 2 diabetes mellitus (a review)
- Repaglinide: A review of its therapeutic use in type 2 diabetes mellitus
- Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: Effect of fibrates and rifampicin
- Ionization, lipophilicity and solubility properties of repaglinide
- Determination of repaglinide in pharmaceutical formulations by HPLC with UV detection
Safety Data Sheet (SDS)
The requested SDS is not available.
Please Contact Us for more information.
The requested SDS is not available.
Specifications
The requested specifications are not available.
Please Contact Us for more information.
The requested specifications are not available.
C of A & Other Certificates
Please check that the lot number you have entered is correct. It is 4-5 alphanumeric characters before the hyphen. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
If your information is correct and you are still not able to view the requested certificates, Please Contact Us for more information.
Please check that the lot number you have entered is correct. It is 7 alphanumeric characters. In particular, please check O (letter) or 0 (number) and I (letter) or 1 (number).
Sample C of A
A sample C of A for this product is not available at this time.
Analytical Charts
The requested analytical chart is not available. Sorry for the inconvenience.